All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Biomarker Testing Will Fuel Next Wave of Treatment Innovations in Breast Cancer

May 1st 2022

Christos Vaklavas, MD, discusses the increasing emphasis on investigating tumor biology in breast cancer, plus the evolving treatment landscapes in HER2-positive breast cancer, hormone receptor–positive, HER2-negative breast cancer, and triple-negative breast cancer.

Ceralasertib Plus Acalabrutinib Shows Early Activity in High-Risk Relapsed/Refractory CLL

April 30th 2022

The combination of ceralasertib and acalabrutinib showed preliminary clinical activity with acceptable tolerability in patients with high-risk, relapsed/refractory chronic lymphocytic leukemia.

NCCN Establishes Standards of Care in Ampullary Adenocarcinoma

April 29th 2022

The National Comprehensive Cancer Network has released new guidelines for ampullary adenocarcinoma, a disease accounting for just 0.2% of all gastrointestinal malignancies.

Extended Follow-Up Confirms Survival Advantage of Adjuvant Capecitabine in Resected Biliary Tract Cancer

April 29th 2022

Adjuvant capecitabine continues to demonstrate an improvement in overall survival compared with observation following curative-intent resection in patients with biliary tract cancer.

Renowned Robotic Surgeon First to Use New 3D Kidney Model

April 29th 2022

Renowned robotic urologic oncology surgeon Dipen J. Parekh, MD, was the first in the nation to test a new preoperative surgical rehearsal technology recently approved by the FDA for all genitourinary conditions.

European Commission Approves Pembrolizumab/Chemotherapy With or Without Bevacizumab for PD-L1+ Metastatic Cervical Cancer

April 29th 2022

The European Commission has granted an approval to the combination of pembrolizumab and chemotherapy, with or without bevacizumab, for the treatment of adult patients with persistent, recurrent or metastatic cervical cancer whose tumors have a PD-L1 combined positive score of 1 or higher.

European Commission Approves Pembrolizumab for Select MSI-H/dMMR Solid Tumors

April 29th 2022

The European Commission has granted an approval to pembrolizumab for the treatment of patients with select microsatellite instability–high or deficient mismatch repair solid tumors.

NCCN Recommends Fifth COVID-19 Shot for Patients with Cancer

April 29th 2022

The National Comprehensive Cancer Network is advising individuals who are immunocompromised, including those with cancer, to receive a fifth COVID-19 vaccination.

COVID-19 Booster Yields Responses After Failure of Initial Vaccine Doses in Prior HCT or CAR T-Cell Therapy Recipients

April 29th 2022

The administration of a third dose of a SARS-CoV-2 mRNA vaccine yielded seroconversion responses in patients treated with hematopoietic cell transplantation or cellular therapy following initial failure of seroconversion after the first 2 vaccine doses.

Building the Community Oncology Practice of the Future Demands a Comprehensive Approach

April 29th 2022

As cancer care continues to shift away from a fee-for-service model to a value-based care model, clinicians and institutions will need to be adaptable and innovative to build effective community oncology practices of the future.

Genomics Guide Treatment, But Novel Agents Generate Excitement in AML and HR-MDS

April 28th 2022

New data ranging from up-front approaches with targeted therapy to maintenance therapy, as well as emerging findings with novel agents continue to push the paradigm forward in acute myeloid leukemia and higher-risk myelodysplastic syndromes.

Novel FSHR-Mediated CAR T Approach Under Exploration in Recurrent Ovarian Cancer

April 28th 2022

An investigative follicle-stimulating hormone receptor–mediated CAR T-cell technology is under exploration in patients with recurrent ovarian cancer.

Enzalutamide Plus ADT Demonstrates Significant Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer

April 28th 2022

Treatment with the androgen-receptor inhibitor enzalutamide plus androgen deprivation therapy led to significant survival benefits in patients with metastatic hormone-sensitive prostate cancer.

FDA Accepts NDA Resubmission for Pedmark in Prevention of Platinum-Induced Ototoxicity in Solid Tumors

April 28th 2022

The FDA has accepted for filing the new drug application resubmission for a unique formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in patients between the ages of 1 month and 18 years who have localized, nonmetastatic, solid tumors.

MD Anderson Receives Over $10 million from Break Through Cancer to Support Collaborative Research With Leading Cancer Centers

April 28th 2022

The University of Texas MD Anderson Cancer Center was awarded more than $10 million in grants to support collaborative research teams working to advance novel interception and treatment strategies that will improve outcomes for several cancer types with the greatest unmet need.

Microbiota Modulation Offers Hope of Expanding the Benefits of Immunotherapy

April 28th 2022

Novel strategies to modulate the microbiota are now an area of robust investigation

Durvalumab Plus Oleclumab or Monalizumab Induces Increased Response Rates in NSCLC

April 28th 2022

Consolidation therapy with durvalumab and either oleclumab or monalizumab showed increased clinical benefits in patients with unresectable stage III non–small cell lung cancer.

JSP191 Plus Fludarabine and Low-Dose Irradiation Produces Promising Early Data in MDS/AML

April 27th 2022

The combination of JSP191, fludarabine, and low-dose total body irradiation demonstrated facilitation of full donor myeloid chimerism, clearance of minimal residual disease, and a tolerable safety profile in patients with myelodysplastic syndrome or acute myeloid leukemia.

Frontline Tislelizumab/Chemo Combo Improves OS in Advanced Esophageal Squamous Cell Carcinoma

April 27th 2022

The combination of tislelizumab and chemotherapy resulted in a significant improvement in overall survival compared with chemotherapy alone in patients with locally advanced, recurrent or metastatic esophageal squamous cell carcinoma, irrespective of PD-L1 expression.

FDA Grants Fast Track Designation to VB-111 for Platinum-Resistant Ovarian Cancer

April 27th 2022

The FDA has granted a fast track designation to VB-111, a targeted anticancer viral gene therapy, for use as a potential therapeutic option in patients with platinum-resistant ovarian cancer.